Clinical trial
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
NCT00282087 · Sarcoma Alliance for Research through Collaboration, Other · Completed
Key facts
| NCT number | NCT00282087 |
|---|---|
| Title | Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma |
| Official title | Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With Gemcitabine/Docetaxel Followed by Doxorubicin: A Phase II Trial |
| Lead sponsor | Sarcoma Alliance for Research through Collaboration, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leiomyosarcoma, Uterine Neoplasm |
| Intervention type | Drug |
| Interventions | gemcitabine, docetaxel, doxorubicin |
| Enrollment | 47 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Jan 25, 2006 |
| Last update posted | Dec 1, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: